{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T14:09:17Z","timestamp":1695737357835},"publisher-location":"Chichester, UK","reference-count":50,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd010475.pub2","type":"reference-entry","created":{"date-parts":[[2013,8,6]],"date-time":"2013-08-06T20:41:32Z","timestamp":1375821692000},"source":"Crossref","is-referenced-by-count":1,"title":["Laquinimod for multiple sclerosis"],"prefix":"10.1002","author":[{"given":"Dian","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangdong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ZhanHui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,8,6]]},"reference":[{"issue":"11","key":"10.1002\/14651858.CD010475.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1056\/NEJMoa1104318","article-title":"Placebo-controlled trial of oral laquinimod for multiple sclerosis","volume":"366","author":"Comi","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"9630","key":"10.1002\/14651858.CD010475.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/S0140-6736(08)60918-6","article-title":"Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study","volume":"371","author":"Comi","year":"2008","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD010475.pub2-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1177\/1352458510378127","article-title":"Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study","volume":"16","author":"Comi","year":"2010","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD010475.pub2-BIB4|cit4","first-page":"420","article-title":"Laquinimod slows disability progression and reduces severe relapses in the placebo-controlled phase III ALLEGRO trial for the treatment of relapsing-remitting multiple sclerosis","volume":"17 Suppl 10","author":"Comi","year":"2011","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD010475.pub2-BIB5|cit5","doi-asserted-by":"crossref","unstructured":"Comi G Vollmer T Sorensen PS Arnold D Filippi M Statinov O Pooled analyses from the ALLEGRO and BRAVO trials on the safety and tolerability of laquinimod as a multiple sclerosis treatment Neurology 2012","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.P04.132"},{"key":"10.1002\/14651858.CD010475.pub2-BIB6|cit6","first-page":"146","article-title":"Oral laquinimod reduces MRI markers suggestive of irreversible tissue damage in RRMS: results from ALLEGRO, a placebo-controlled phase III trial","volume":"17 Suppl 10","author":"Filippi","year":"2011","journal-title":"Multiple Sclerosis"},{"issue":"6","key":"10.1002\/14651858.CD010475.pub2-BIB7|cit7","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1212\/01.WNL.0000154520.48391.69","article-title":"Treatment with laquinimod reduces development of active MRI lesions in relapsing MS","volume":"64","author":"Polman","year":"2005","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD010475.pub2-BIB8|cit8","doi-asserted-by":"crossref","unstructured":"Vollmer T Comi G Sorensen PS Arnold D Filippi M Statinova O Clinical efficacy of laquinimod for the treatment of multiple sclerosis; pooled analyses from the ALLEGRO and BRAVO phase III trials Neurology 2012","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.S01.007"},{"key":"10.1002\/14651858.CD010475.pub2-BIB9|cit9","first-page":"S507-24, Abstra","article-title":"A placebo-controlled and active comparator phase III trial (BRAVO) for relapsing-remitting multiple sclerosis","volume":"17","author":"Vollmer","year":"2011","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD010475.pub2-BIB10|cit10","unstructured":"The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) (CONCERTO) http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01707992 (Accessed 10 July 2013)"},{"issue":"1-2","key":"10.1002\/14651858.CD010475.pub2-BIB11|cit11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jneuroim.2012.06.005","article-title":"Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis","volume":"251","author":"Aharoni","year":"2012","journal-title":"Journal of Neuroimmunology"},{"issue":"2","key":"10.1002\/14651858.CD010475.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1212\/01.wnl.0000316802.35974.34","article-title":"Temporal trends in the incidence of multiple sclerosis: a systematic review","volume":"71","author":"Alonso","year":"2008","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD010475.pub2-BIB13|cit13","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nrneurol.2009.41","article-title":"Imaging outcomes for neuroprotection and repair in multiple sclerosis trials","volume":"5","author":"Barkhof","year":"2009","journal-title":"Nature Reviews Neurology"},{"issue":"1-2","key":"10.1002\/14651858.CD010475.pub2-BIB14|cit14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0165-5728(02)00225-4","article-title":"The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis","volume":"130","author":"Brunmark","year":"2002","journal-title":"Journal of Neuroimmunology"},{"issue":"1-2","key":"10.1002\/14651858.CD010475.pub2-BIB15|cit15","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jns.2011.02.019","article-title":"Insight into the mechanism of laquinimod action","volume":"306","author":"Br\u00fcck","year":"2011","journal-title":"Journal of the Neurological Sciences"},{"issue":"3","key":"10.1002\/14651858.CD010475.pub2-BIB16|cit16","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00401-012-1009-1","article-title":"Reduced astrocytic NF-\u03baB activation by laquinimod protects from cuprizone-induced demyelination","volume":"124","author":"Br\u00fcck","year":"2012","journal-title":"Acta Neuropathology"},{"issue":"12","key":"10.1002\/14651858.CD010475.pub2-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1136\/jnnp.2008.171090","article-title":"New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate","volume":"80","author":"Cadavid","year":"2009","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"Pt 3","key":"10.1002\/14651858.CD010475.pub2-BIB18|cit18","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/brain\/awl007","article-title":"Natural history of multiple sclerosis: a unifying concept","volume":"129","author":"Confavreux","year":"2006","journal-title":"Brain"},{"issue":"2","key":"10.1002\/14651858.CD010475.pub2-BIB19|cit19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.nrl.2010.07.027","article-title":"Oral laquinimod treatment in multiple sclerosis","volume":"26","author":"Fern\u00e1ndez","year":"2011","journal-title":"Neurologia"},{"issue":"11","key":"10.1002\/14651858.CD010475.pub2-BIB20|cit20","first-page":"677","article-title":"Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I)","volume":"54","author":"Fern\u00e1ndez","year":"2012","journal-title":"Revista de Neurologia"},{"key":"10.1002\/14651858.CD010475.pub2-BIB21|cit21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/01.wco.0000413320.94715.e9","article-title":"New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis","volume":"25 Suppl 1","author":"Fox","year":"2012","journal-title":"Current Opinion in Neurology"},{"key":"10.1002\/14651858.CD010475.pub2-BIB22|cit22","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010475.pub2-BIB23|cit23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2377-11-153","article-title":"Gray matter imaging in multiple sclerosis: what have we learned?","volume":"11","author":"Hulst","year":"2011","journal-title":"BMC Neurology"},{"issue":"1","key":"10.1002\/14651858.CD010475.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.euroneuro.2011.05.001","article-title":"The socioeconomic consequences of multiple sclerosis: a controlled national study","volume":"22","author":"Jennum","year":"2012","journal-title":"European Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD010475.pub2-BIB25|cit25","first-page":"e11","article-title":"Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada","volume":"19","author":"Karampampa","year":"2012","journal-title":"Journal of Population Therapeutics and Clinical Pharmacology"},{"key":"10.1002\/14651858.CD010475.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurological impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD010475.pub2-BIB27|cit27","doi-asserted-by":"crossref","first-page":"518","DOI":"10.2174\/187152712801661185","article-title":"Optical coherence tomography detection of neurodegeneration in multiple sclerosis","volume":"11","author":"Lidster","year":"2012","journal-title":"Current Drug Targets-CNS & Neurological Disorders"},{"key":"10.1002\/14651858.CD010475.pub2-BIB28|cit28","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD010475.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD010475.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ajpath.2012.05.011","article-title":"Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod","volume":"181","author":"Mishra","year":"2012","journal-title":"The American Journal of Pathology"},{"issue":"5","key":"10.1002\/14651858.CD010475.pub2-BIB31|cit31","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2165\/11532230-000000000-00000","article-title":"Economic burden of multiple sclerosis: a systematic review of the literature","volume":"28","author":"Naci","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"10.1002\/14651858.CD010475.pub2-BIB32|cit32","unstructured":"National MS Society Who gets MS? http:\/\/www.nationalmssociety.org\/about-multiple-sclerosis\/what-we-know-aboutms\/who-gets-ms\/index.aspx (Accessed 29 November 2012)"},{"issue":"1","key":"10.1002\/14651858.CD010475.pub2-BIB33|cit33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2165\/11592160-000000000-00000","article-title":"Burden of a multiple sclerosis relapse: the patient's perspective","volume":"5","author":"Oleen-Burkey","year":"2012","journal-title":"Patient"},{"issue":"1","key":"10.1002\/14651858.CD010475.pub2-BIB34|cit34","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1471-2377-12-94","article-title":"Social and economic burden of walking and mobility problems in multiple sclerosis","volume":"12","author":"Pike","year":"2012","journal-title":"BMC Neurology"},{"issue":"6","key":"10.1002\/14651858.CD010475.pub2-BIB35|cit35","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \"McDonald Criteria\"","volume":"58","author":"Polman","year":"2005","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD010475.pub2-BIB36|cit36","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Annals of Neurology"},{"issue":"8","key":"10.1002\/14651858.CD010475.pub2-BIB37|cit37","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis:guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Annals of Neurology"},{"issue":"7","key":"10.1002\/14651858.CD010475.pub2-BIB38|cit38","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1517\/13543780903044944","article-title":"Oral laquinimod therapy in relapsing multiple sclerosis","volume":"18","author":"Preiningerova","year":"2009","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1002\/14651858.CD010475.pub2-BIB39|cit39","unstructured":"Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2012"},{"issue":"3","key":"10.1002\/14651858.CD010475.pub2-BIB40|cit40","doi-asserted-by":"crossref","first-page":"e33797","DOI":"10.1371\/journal.pone.0033797","article-title":"Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity","volume":"7","author":"Schulze-Topphoff","year":"2012","journal-title":"PLOS One"},{"issue":"3","key":"10.1002\/14651858.CD010475.pub2-BIB41|cit41","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jama.2012.7625","article-title":"Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis","volume":"308","author":"Shirani","year":"2012","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD010475.pub2-BIB42|cit42","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ajpath.2011.09.037","article-title":"Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor","volume":"180","author":"Th\u00f6ne","year":"2012","journal-title":"The American Journal of Pathology"},{"issue":"1-2","key":"10.1002\/14651858.CD010475.pub2-BIB43|cit43","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jneuroim.2012.07.003","article-title":"Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis","volume":"251","author":"Toubi","year":"2012","journal-title":"Journal of Neuroimmunology"},{"issue":"4","key":"10.1002\/14651858.CD010475.pub2-BIB44|cit44","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1191\/1352458504ms1059oa","article-title":"Clinical characteristics of progressive relapsing multiple sclerosis","volume":"10","author":"Tullman","year":"2004","journal-title":"Multiple Sclerosis"},{"issue":"6","key":"10.1002\/14651858.CD010475.pub2-BIB45|cit45","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1124\/dmd.104.002238","article-title":"Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator","volume":"33","author":"Tuvesson","year":"2005","journal-title":"Drug Metabolism and Disposition"},{"issue":"10","key":"10.1002\/14651858.CD010475.pub2-BIB46|cit46","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00234-009-0645-1","article-title":"Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis","volume":"52","author":"Elskamp","year":"2010","journal-title":"Neuroradiology"},{"issue":"1-2","key":"10.1002\/14651858.CD010475.pub2-BIB47|cit47","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jneuroim.2010.07.009","article-title":"Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis","volume":"227","author":"Wegner","year":"2010","journal-title":"Journal of Neuroimmunology"},{"issue":"1-2","key":"10.1002\/14651858.CD010475.pub2-BIB48|cit48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jneuroim.2004.02.016","article-title":"Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1\/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats","volume":"156","author":"Yang","year":"2004","journal-title":"Journal of Neuroimmunology"},{"key":"10.1002\/14651858.CD010475.pub2-BIB49|cit49","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.2741\/e475","article-title":"Magnetization transfer imaging of acute black holes in patients on glatiramer acetate","volume":"4","author":"Zivadinov","year":"2012","journal-title":"Frontiers in Bioscience (Elite Edition)"},{"issue":"5","key":"10.1002\/14651858.CD010475.pub2-BIB50|cit50","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0028-3908(02)00015-1","article-title":"Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1\/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue","volume":"42","author":"Zou","year":"2002","journal-title":"Neuropharmacology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T07:57:02Z","timestamp":1625039822000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/14651858.CD010475.pub2"}},"subtitle":[],"editor":[{"given":"Lan","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,8,6]]},"references-count":50,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010475.pub2","relation":{},"subject":[],"published":{"date-parts":[[2013,8,6]]}}}